Baidu
map

2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用

2022-01-20 免疫实践咨询委员会 MMWR Morb Mortal Wkly Rep

2022年1月,免疫实践咨询委员会(ACIP)发布了重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用建议。本文更新了ACIP关于免疫功能低下成人(≥19岁)预防带状疱疹的疫苗接种建议。

中文标题:

2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用

英文标题:

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

发布机构:

免疫实践咨询委员会

发布日期:

2022-01-20

简要介绍:

2022年1月,免疫实践咨询委员会(ACIP)发布了重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用建议。本文更新了ACIP关于免疫功能低下成人(≥19岁)预防带状疱疹的疫苗接种建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0c26b1c002331616, title=2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用, enTitle=Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022, guiderFrom=MMWR Morb Mortal Wkly Rep, authorId=0, author=, summary=2022年1月,免疫实践咨询委员会(ACIP)发布了重组带状疱疹疫苗在免疫功能低下成人(&ge;19岁)中的应用建议。本文更新了ACIP关于免疫功能低下成人(≥19岁)预防带状疱疹的疫苗接种建议。, cover=https://img.medsci.cn/2022121/1642741673377_1608702.jpg, journalId=0, articlesId=null, associationId=469, associationName=免疫实践咨询委员会, associationIntro=Immunization Action Coalition下分支,服务于疾病控制和预防中心(CDC),制定免疫计划及推荐疫苗使用建议。, copyright=0, guiderPublishedTime=Thu Jan 20 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年1月,免疫实践咨询委员会(ACIP)发布了重组带状疱疹疫苗在免疫功能低下成人(&ge;19岁)中的应用建议。本文更新了ACIP关于免疫功能低下成人(&ge;19岁)预防带状疱疹的疫苗接种建议。</span></p>, tagList=[TagDto(tagId=27230, tagName=皮肤疾病), TagDto(tagId=121931, tagName=重组带状疱疹疫苗)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=1, paymentType=, paymentAmount=0, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5775, appHits=65, showAppHits=0, pcHits=633, showPcHits=5710, likes=0, shares=5, comments=2, approvalStatus=1, publishedTime=Fri Jan 21 13:05:26 CST 2022, publishedTimeString=2022-01-20, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Jan 21 13:09:54 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 12:04:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用.pdf)])
2022 ACIP建议:重组带状疱疹疫苗在免疫功能低下成人(≥19岁)中的应用.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1187584, encodeId=42d3118e58437, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:09:27 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187068, encodeId=ba64118e0680e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 22 07:22:44 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-24 胡国宏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1187584, encodeId=42d3118e58437, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Jan 24 07:09:27 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187068, encodeId=ba64118e0680e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 22 07:22:44 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 微探

    学习学习

    0

Baidu
map
Baidu
map
Baidu
map